SELLAS Life Sciences Group, Inc. (SLS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US81642T2096
SELLAS Life Sciences Group, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -28.27 m USD |
| EBIT | -26.86 m USD |
| Net income | -26.86 m USD |
| Diluted EPS – continuing operations | -0.25 USD |
Full history since 2006, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
More stocks
- CIMC Vehicles (Group) Co. Ltd. (301039.SZ)
- Arlo Technologies, Inc. (ARLO)
- Ping AN Healthcare and Technology Co Ltd (1833.HK)
- Implenia AG (IMPN.SW)
- Dampskibsselskabet Norden A/S (DNORD.CO)
- PATHWARD FINANCIAL, INC. (CASH)
- Lotte Rental Co Ltd (089860.KS)
- Cymbria Corporation (CYB.TO)
- Zhejiang Jingxin Pharmaceutical Co Ltd (002020.SZ)
- Global Net Lease, Inc. (GNL)
- Shenzhen Colibri Technologies Co Ltd (002957.SZ)
- Ultragenyx Pharmaceutical Inc. (RARE)
Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.